ankeda bevacizumab injection 100mg 4ml per vial

Description

Indication & Scope

Bevacizumab Injection (AnKeDa®) specifically binds to vascular endothelial growth factor (VEGF), inhibiting VEGF-mediated angiogenesis, reducing tumor blood supply, suppressing tumor growth and metastasis.

Mechanism
Neutralize VEGF, inhibit tumor angiogenesis, cut off tumor nutrient supply, slow tumor progression and metastasis
Drug class
Anti-tumor Monoclonal Antibody / Anti-angiogenic Agent
Clinical use
Treatment of multiple malignant solid tumors including metastatic colorectal cancer, advanced non-small cell lung cancer, recurrent glioblastoma, hepatocellular carcinoma, ovarian cancer and cervical cancer

Specification

Generic Name	Bevacizumab Injection
Brand Name	AnKeDa®
Ingredient	Bevacizumab
Dosage Form	Soulution for injection
Package	100mg:4ml/vial
Conditions Treated	Metastatic colorectal cancer; advanced, metastatic or recurrent non-squamous non-small cell lung cancer; recurrent glioblastoma; unresectable hepatocellular carcinoma; epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer; persistent, recurrent or metastatic cervical cancer
Taboos	Hypersensitivity to bevacizumab or any excipients
Place of origin	Shandong,China
Priscription Type	Prescription drug (Rx)
Storage Conditions	Store and transport at 2℃-8℃, protect from light, do not freeze or shake vigorously
Manufacturer	Qilu Pharmaceutical Co., Ltd.
Registration Authority	National Medical Products Administration (NMPA)
Approval number	S20258014
Date of Revision	August 13, 2025
Shelf Life	24 months

How to use ?

Recommended Dose: Dosing varies by indication (e.g., 5mg/kg q2w or 7.5mg/kg q3w for metastatic colorectal cancer; 15mg/kg q3w for non-small cell lung cancer), administered by intravenous infusion under physician supervision, do not give as rapid IV push

Time: Infuse intravenously per official instructions; first infusion over 90 minutes, subsequent infusions may be shortened if tolerated

Interaction: Risk of enhanced adverse effects with other anti-angiogenic agents; avoid major surgery within 28 days before/after administration; monitor concurrent chemotherapy regimens

Side effects: Hypertension, proteinuria, bleeding, gastrointestinal perforation, arterial thromboembolism, wound healing complications, fatigue, diarrhea, infection, infusion reactions

Important Notice

This product shall only be used for post-exposure rabies prophylaxis by professional medical staff. It must be applied combined with rabies vaccine and injected via wound infiltration plus intramuscular routes as specified. Do not administer intravenously or alter the dosage at will. Hypersensitivity monitoring is required throughout the whole injection process.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support